Combination Treatment for Rare Prostate Cancer
Author Information
Author(s): Fei Xin, Zheng Zhong, Zhao Zhen-ya, Ren Da-wei, Wang Su-ying, Ye Shi-jie, Liang Lin-chun, Li Da, Jia Xiao-long, Ma Qi
Primary Institution: Ningbo University, Ningbo, China
Hypothesis
Can anlotinib combined with tislelizumab improve outcomes in patients with primary small cell neuroendocrine carcinoma of the prostate?
Conclusion
The combination of anlotinib and tislelizumab led to significant tumor shrinkage and prolonged progression-free survival in a patient with advanced prostate cancer.
Supporting Evidence
- The patient had a progression-free survival time of more than 22 months after treatment.
- Imaging showed significant improvement after the combination therapy.
- The patient experienced no significant side effects during the treatment.
Takeaway
A patient with a rare type of prostate cancer was treated with two drugs together, and it helped him feel better and live longer than expected.
Methodology
The patient received anlotinib and tislelizumab after failing standard chemotherapy, with treatment cycles every three weeks.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
An elderly male patient with advanced primary small cell neuroendocrine carcinoma of the prostate.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website